Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology May 21, 2020August 16, 2022
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial February 16, 2023May 23, 2023